Development of Visual and Fluorescence Detection Method of Brucella by RPA-CRISPR/Cas12a Assay
- PMID: 41474367
- DOI: 10.1096/fj.202503610R
Development of Visual and Fluorescence Detection Method of Brucella by RPA-CRISPR/Cas12a Assay
Abstract
Brucella is a significant pathogen in the livestock industry, causing Brucellosis, a zoonotic disease that leads to considerable health and economic losses in both humans and animals. Current diagnostic methods for Brucella, including culture, serological assays, and PCR/qPCR, are valuable tools but have inherent limitations. These include the requirement for BSL-3 laboratories, trained personnel, complex procedures, expensive equipment, issues with sensitivity and specificity, and the time-consuming nature of assays, making them unsuitable for large-scale epidemiological screening. Therefore, there is a critical need to develop a rapid, portable, and cost-effective diagnostic method with high specificity and sensitivity. In this study, we established a rapid, portable, reliable, and inexpensive detection method for Brucella genus identification based on RPA-CRISPR/Cas12a technology. Specific RPA primers and crRNA sequences were designed targeting the bcsp31 gene of Brucella. Subsequently, both a fluorescence assay and a lateral flow strip (LFS) assay were developed after optimizing the conditions using the RPA-CRISPR/Cas12a system. The limit of detection (LoD) was 1 copy/μL for RPA-CRISPR/Cas12a-F and 10 copies/μL for RPA-CRISPR/Cas12a-LFS and the entire assay was completed in less than 30 min. This method demonstrated excellent specificity in distinguishing Brucella from other closely related pathogens. Moreover, the RPA-CRISPR/Cas12a assay showed high concordance with classical quantitative real-time PCR when testing diverse clinical samples (blood, serum, milk, semen, vaginal secretions). Together, these findings make this method a promising tool for Brucella detection, with potential applications in both field surveillance and clinical diagnostics.
Keywords: Brucella; CRISPR; RPA; molecular diagnostics; sensitivity; specificity.
© 2025 Federation of American Societies for Experimental Biology.
References
-
- M. H. Sadaqat, “Pathogenesis, Clinical Manifestations, Treatment and Prevention of Brucellosis in Humans and Animals,” Afghanistan Journal of Basic Medical Science 1 (2024): 85–90.
-
- G. Wareth, M. Dadar, H. Ali, et al., “The Perspective of Antibiotic Therapeutic Challenges of Brucellosis in the Middle East and North African Countries: Current Situation and Therapeutic Management,” Transboundary and Emerging Diseases 69 (2022): e1253–e1268.
-
- T. H. Hasan, H. A. Kadhum, and K. K. Alasedi, “Brucella spp. Virulence factors,” International Journal of Pharmaceutical Research (09752366) 13 (2021): e088.
-
- A. Daugaliyeva, S. Daugaliyeva, N. Kydyr, and S. Peletto, “Molecular Typing Methods to Characterize Brucella spp. From Animals: A Review,” Veterinary World 17 (2024): 1778–1788.
-
- B. Kurmanov, D. Zincke, W. Su, et al., “Assays for Identification and Differentiation of Brucella Species: A Review,” Microorganisms 10 (2022): 1584.
MeSH terms
Grants and funding
- 2022YFC2304001/MOST | National Key Research and Development Program of China (NKPs)
- 2024BEG-02029/The Key Research and Development Program of Ningxia Hui Autonomous Region
- 2024312885/Comprehensive Control Technology For Brucellosis and Hydatic Disease in Xinjiang
- CAAS-ZDRW202410/The Agricultural Science and Technology Innovation Program (ASTIP)
LinkOut - more resources
Full Text Sources
